---

---

t-cell   tags : Sars-cov-2   

save search

---

Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains
Published: 2022-10-13 (Crawled : 13:00) - prnewswire.com
NVAX | $4.15 -0.96% -0.96% 2M |

Health Technology

| -79.5% | O: -5.01% H: 13.34% C: 10.69%
covid-19 candidate antibody vaccine t-cell sars-cov-2 influenza

---

Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2
Published: 2022-01-11 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310 |

Health Technology

| -8.06% | O: -3.41% H: 5.99% C: 1.1%
TNXP | $0.16 2.04% 1.2% 940K |

Health Technology

| -50.16% | O: 0.75% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| -5.39% | O: 1.58% H: 0.0% C: 0.0%
sars-cov-2 enroll t-cell diagnostic

---

Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
Published: 2021-12-28 (Crawled : 06:00) - globenewswire.com
NKTR | News | $1.38 -2.82% -2.16% 960K |

Health Technology

| -91.03% | O: -0.91% H: 1.18% C: -1.31%
therapeutics cel sars-cov-2 vaccine t-cell

---

Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310 |

Health Technology

| -3.7% | O: -3.62% H: 0.0% C: -0.56%
TNXP | $0.16 2.04% 1.2% 940K |

Health Technology

| -58.39% | O: 5.33% H: 0.0% C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M |

Health Technology

| -2.38% | O: -0.51% H: 0.0% C: 0.0%
tnx-2100 als clearance skin cel sars-cov-2 test t-cell

---

QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
Published: 2021-12-02 (Crawled : 09:00) - biospace.com/
QGEN | $41.52 -0.88% 0.0% 820K |

Health Technology

| -22.93% | O: 0.78% H: 0.88% C: 0.5%
QGEN | $41.52 -0.88% 0.0% 820K |

Health Technology

| -22.93% | O: 0.78% H: 0.88% C: 0.5%
covid quantiferon t-cell sars-cov-2 response

---

The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GRTS | $0.8129 10.06% 9.92% 1.8M |

Health Technology

| -92.64% | O: 2.95% H: 0.66% C: -7.28%
covid vaccine sars-cov-2 t-cell

---

Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
ALVR | $0.78 -1.38% -1.06% 120K |

Health Technology

| -96.84% | O: 1.46% H: 2.47% C: -0.76%
therapy sars-cov-2 t-cell

---

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern
Published: 2021-06-09 (Crawled : 12:00) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M |

Health Technology

| -9.33% | O: 0.37% H: 1.09% C: 0.98%
ADPT | $2.6 0.78% 0.39% 2M |

Commercial Services

| -92.64% | O: 0.82% H: 3.0% C: 0.59%
covid vaccine t-cell sars-cov-2

---

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT Study to Investigate the T Cell Response and COVID Vaccination in Ethnic Minority Groups
Published: 2021-04-29 (Crawled : 14:00) - globenewswire.com
PKI | $115.24 0.0% 1.6M |

Health Technology

| -13.14% | O: 0.08% H: 0.09% C: -2.61%
covid ford test sars-cov-2 vaccine t-cell

---

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
Published: 2021-04-27 (Crawled : 14:00) - biospace.com/
PKI | $115.24 0.0% 1.6M |

Health Technology

| -13.84% | O: 0.34% H: 0.32% C: -0.32%
covid ford test vaccine trial sars-cov-2 t-cell

---

Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
Published: 2021-02-08 (Crawled : 12:25) - globenewswire.com
TNXP | $0.16 2.04% 1.2% 940K |

Health Technology

| -87.4% | O: 30.63% H: 0.06% C: -6.57%
covid test skin t-cell sars-cov-2

---

Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
Published: 2020-09-15 (Crawled : 13:59) - globenewswire.com
TNXP | $0.16 2.04% 1.2% 940K |

Health Technology

| -79.22% | O: 7.81% H: 4.82% C: -3.54%
covid antibody t-cell sars-cov-2 enroll

---

Gainers vs Losers

61%

39%

Top 10 Gainers

CSSE 4 | $0.4253 179.25% 64.77% 210M |

Consumer Services

BOF | $2.08 77.78% 41.21% 110M |

ILAG | $0.54 12.27% 40.62% 3.7M |

LICN | $0.999 78.39% 40.49% 15M |

AMST | $3.4 70.0% 39.58% 70M |

Technology Services

MTC | $3.6 60.71% 38.04% 9.1M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.458 14.5% 30.92% 91K |

Health Services

WHLM | $6.25 35.87% 28.46% 700K |

Commercial Services

MULN | News | $3.77 38.1% 27.78% 13M |

Information

---

Your saved searches

---